Tokyo: Life Sciences and Health Care Horizons 2019

Key Life Sciences issues for Japanese companies: focus on (1) digital health, (2) cell, tissue, and gene therapies, and (3) cross-border transactions.

Essential corporate, tax, regulatory and IP issues for Japanese companies expanding in Europe

In the light of the continued increase in significant mergers and acquisitions (M&A) and licensing transactions worldwide, in particular the significant increase of out-bound...

Loading data